CPA Releases Recommendations for Bilateral Trade Actions
CPA’s new Trade Issues and Tariff Recommendation Tracker highlights specific tariff recommendations that will produce near-term wins.
CPA’s new Trade Issues and Tariff Recommendation Tracker highlights specific tariff recommendations that will produce near-term wins.
In a comment letter submitted to USTR in response to the Section 301 investigation, CPA highlighted China’s extensive use of state-driven subsidies and unfair trade practices, urging immediate implementation of targeted measures to support the revitalization of the U.S. shipbuilding industry.
It’s been five years in the making, yet a bill requiring online retailers to label the country of origin for merchandise remains a tough sell in Congress—even among the lawmakers who introduced it back in 2020.
It’s been a rough start to 2025 for Indian pharmaceutical giants. Four of India’s biggest generic drug producers issued product recalls in the last three months.
CPA cautions against adopting a reciprocal tariff strategy aimed primarily at negotiating lower foreign trade barriers and more favorable investment conditions abroad. A reciprocal tariff strategy that prioritizes foreign governments’ willingness to reduce their trade barriers or be more receptive to foreign investment is in conflict with the stated goals of the America First Trade Policy Memorandum and undermines the predictability and stability American businesses need to confidently invest in long-term domestic production.
It’s a straight line up. The goods and services deficit kicked off January by rising a record 34% over December. Importers are front running tariffs and getting in their orders before everything changes, likely at some point after April 1.
It took nine months to rescue two astronauts stuck on the International Space Station this weekend, yet somehow President Trump is expected to rewrite global trade rules between the U.S. and 166 World Trade Organization-member countries in less than two months.
Strong federal investment in the National Science Foundation and National Institutes of Health is vital for American innovation, economic growth, and national security.
For years, the de minimis loophole has flooded the U.S. with uninspected, untaxed, and often dangerous goods—from counterfeit products to fentanyl precursors fueling America’s opioid crisis.
Investors’ panic is misguided—history proves President Trump’s tariffs boost investment, jobs, and long-term American prosperity.
Notifications